Pharma & Biotech Insights, Interviews & Features
Biotechnology
19 November 2024 19 November 2024
Today's issue
Refine Search
Biotechnology
In August 2020, Russia approved its homegrown coronavirus vaccine Sputnik V, months ahead of rival programs in the west. Episode 8 of The Pharma Letter Podcast features Kirill Dmitriev, chief executive of the vaccine's backer, RDIF. 14 December 2021
Pharmaceutical
Real world evidence (RWE) continues to grow as a promising frontier in evidence generation to support positive health outcomes. It can be useful in evaluating unmet healthcare needs, real world standard of care, and patient-reported outcomes, as well as developing realistic trial designs and budget impact models. 13 December 2021
Pharmaceutical
Virtually every drugmaker with a presence in hematology is preparing for their end-of-year attempt to impress physicians and investors with the best of their freshest data at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2021
Generics
Supply chain disruptions, quality concerns and abrupt price hikes have been some of the issues resulting from over-dependency on a single source for supplies of life-saving drugs and other key raw materials. To mitigate risks associated with over-dependency on other nations, India's Health Minister Mansukh Mandaviya says the focus is to build self-reliance and promote the domestic pharmaceutical manufacturing industry, despite the decision to shut down two pharma public sector undertakings and disinvest three others, reports The Pharma Letter’s India correspondent. 9 December 2021
Pharmaceutical
An Expert View on the importance of embedding a modern quality culture from David Fryrear, executive vice president and head of quality assurance, Medical and Development, Astellas Pharma Global Development. 9 December 2021
Pharmaceutical
The Russian government will allocate about 62 billion roubles ($840 million) in 2022 for the procurements of high-priced drugs as part of the 14 high-cost nosologies (14 VZN) program, a state program, which involves procurements of the most expensive drugs for state needs in Russia, reports The Pharma Letter’s local correspondent. 7 December 2021
Pharmaceutical
The updated Chinese national drug reimbursement list, released on December 3 by the National Healthcare security Administration (NHSA), showed clearly that China wants more affordable rare disease drugs and innovative cancer drugs, reports The Pharma Letter’s local correspondent. 6 December 2021
Generics
The key issue when prescribing generic drugs in India is quality, not price, with Indian doctors relying on the reputation of companies that have demonstrated their commitment to quality over time. A new study has found that the perceived difference in the quality of various brands of generic drugs that can be prescribed interchangeably is one of the major barriers to effective price competition in India's drug market, reports The Pharma Letter’s India correspondent. 2 December 2021
Biotechnology
The Johnson & Johnson unit Janssen has been active in neuroscience since the beginnings of the company, with its first product coming in this space, so each new major breakthrough in the area is a continuation of a rich tradition. 1 December 2021
Biotechnology
Chinese biotechs used to prefer late-clinical stage assets when seeking in-licensing targets for a quick launch in China, but this is no longer the case. 1 December 2021
Pharmaceutical
Vicki Pearson, global solutions architect, life sciences at Schneider Electric, provides an Expert View on how firms can meet a growing demand while remaining affordable and accessible. 30 November 2021
Pharmaceutical
Russia is getting closer to the completion of development of one of the world’s first drugs against COVID-19, according to recent statements by the Russian Health Minister Mikhail Murashko and some local media, reports The Pharma Letter’s local correspondent.
November 23, 2021 30 November 2021
Pharmaceutical
Russia will continue to depend on imports of radiopharmaceuticals in the coming years, as the launch of its own production of such drugs will be suspended for an indefinite period of time, reports The Pharma Letter’s local correspondent. 29 November 2021
Pharmaceutical
Not many companies in the pharmaceutical sector can say that they have kept growing and targeting growth through the pandemic, while maintaining the same commitment to their values, patients and employees. 26 November 2021
Pharmaceutical
Multinationals corporations (MNCs) have been actively adding China to their multicenter global clinical studies in recent years, it was made clear at a recent meeting. 24 November 2021
Pharmaceutical
November 17th was Smith-Magenis syndrome (SMS) Awareness Day. We take a look at this complex development disorder and advances in pharmacological treatments for the condition. 23 November 2021
Generics
The Russian government plans to conduct a pilot project in the domestic pharmaceutical sector that will involve conducting state procurements of drugs manufactured by companies that have a full-cycle production in one of the countries of the Eurasian Economic Union (EAEU). 23 November 2021
Biosimilars
Typically, in the USA, the list prices of biosimilars at launch have been 15% to 35% lower than that of the corresponding reference products, and the biosimilar market is estimated to lead to savings of $133 billion over the next five years.1,2 22 November 2021
Biotechnology
China’s biotech industry enjoyed significant growth in the past several years, but major bottlenecks are looming as Chinese biotechs aims for a global expansion, said speakers at the two-day event Chinatrials on November 11 in Shanghai. 17 November 2021
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) regularly calls out drugmakers in certain therapy areas for introducing drugs to the market at prices that exceed its estimates of what they are worth. 16 November 2021
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze